These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 21907085)

  • 1. New approaches to therapy.
    Brotchie J; Jenner P
    Int Rev Neurobiol; 2011; 98():123-50. PubMed ID: 21907085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
    Fox SH; Chuang R; Brotchie JM
    Prog Brain Res; 2008; 172():479-94. PubMed ID: 18772047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nondopaminergic mechanisms in levodopa-induced dyskinesia.
    Brotchie JM
    Mov Disord; 2005 Aug; 20(8):919-31. PubMed ID: 16007614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities.
    Jenner P
    Mov Disord; 2008; 23 Suppl 3():S585-98. PubMed ID: 18781676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
    Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
    Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanisms of L-DOPA-induced dyskinesia.
    Jenner P
    Nat Rev Neurosci; 2008 Sep; 9(9):665-77. PubMed ID: 18714325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of adenosine receptors with other receptors from therapeutic perspective in Parkinson's disease.
    Morin N; Di Paolo T
    Int Rev Neurobiol; 2014; 119():151-67. PubMed ID: 25175965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease.
    Huot P; Johnston TH; Koprich JB; Fox SH; Brotchie JM
    Pharmacol Rev; 2013 Jan; 65(1):171-222. PubMed ID: 23319549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM
    Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
    Bezard E; Brotchie JM; Gross CE
    Nat Rev Neurosci; 2001 Aug; 2(8):577-88. PubMed ID: 11484001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levodopa-induced dyskinesia in Parkinson's disease.
    Brotchie JM; Lee J; Venderova K
    J Neural Transm (Vienna); 2005 Mar; 112(3):359-91. PubMed ID: 15614429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
    Kobylecki C; Cenci MA; Crossman AR; Ravenscroft P
    J Neurochem; 2010 Jul; 114(2):499-511. PubMed ID: 20456008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine receptors and L-dopa-induced dyskinesia.
    Berthet A; Bezard E
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S8-12. PubMed ID: 20123563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging drugs for levodopa-induced dyskinesia.
    Al Dakheel A; Beaulieu-Boire I; Fox SH
    Expert Opin Emerg Drugs; 2014 Sep; 19(3):415-29. PubMed ID: 25146568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular mechanisms of l-DOPA-induced dyskinesia.
    Fisone G; Bezard E
    Int Rev Neurobiol; 2011; 98():95-122. PubMed ID: 21907084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
    Zhang H; Ma L; Wang F; Chen J; Zhen X
    Neuropharmacology; 2007 Jul; 53(1):125-33. PubMed ID: 17553535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P; Tremblay L; Féger J; Hirsch EC
    Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
    Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
    J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noradrenergic drugs for levodopa-induced dyskinesia.
    Colosimo C; Craus A
    Clin Neuropharmacol; 2003; 26(6):299-305. PubMed ID: 14646609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.